Abstract
Cardiorenal protective effects of sodium–glucose cotransporter 2 inhibitors are difficult to explain. From the recent works by Takagi et al. and an expert consensus report, I suggest further works on the effects of sodium–glucose cotransporter 2inhibitors on mitochondrial function could help to understand this very interesting development.
MeSH terms
-
Clinical Trials as Topic
-
Heart Failure / prevention & control*
-
Humans
-
Kidney Diseases / drug therapy*
-
Mitochondria / drug effects*
-
Protective Agents / therapeutic use*
-
Sodium-Glucose Transporter 2 Inhibitors / administration & dosage*
-
Treatment Outcome
Substances
-
Protective Agents
-
Sodium-Glucose Transporter 2 Inhibitors